Castrate Resistant Prostate Cancer Market, By Therapy Type (Hormonal Therapy, Immunotherapy, Chemotherapy, Radiotherapy), By Drug Class (Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Microtubule Inhibitor, Others), By Route of Administratio

Castrate Resistant Prostate Cancer Market, By Therapy Type (Hormonal Therapy, Immunotherapy, Chemotherapy, Radiotherapy), By Drug Class (Antineoplastic, Non-steroidal Antiandrogen, Corticosteroids, Microtubule Inhibitor, Others), By Route of Administration (Oral and Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Global castrate resistant prostate cancer market growth is driven by rising prevalence of prostate cancer worldwide. Prostate cancer is one of the commonly occurring cancers among men. According to the data from American Cancer Society in 2020, around 191,930 new cases of prostate cancer were reported in the U.S. Once the cancer has metastasized and started growing despite medical or surgical therapy to reduce testosterone levels or block its action, it is termed as castrate resistant prostate cancer (CRPC). Currently available treatment options for CRPC include chemotherapy, immunotherapy, radiation therapy, and others. However, development of resistance remains a major challenge in effectively managing this advanced stage of prostate cancer. Ongoing research for novel drug targets and therapeutic approaches can overcome treatment resistance and improve patient outcomes in CRPC.

Market Dynamics:

Global castrate resistant prostate cancer market growth is driven by rising geriatric population susceptible to developing prostate cancer. According to the data from UN World Population Prospects 2019, the number of people aged 65 years or above is projected to grow from 703 million in 2019 to 1.5 billion in 2050 globally. Increasing awareness and screening rates have also augmented the early detection of prostate cancer, thus, driving the market growth. However, high treatment costs associated with immunotherapy and targeted therapy regimens can hamper the market growth. Ongoing research to develop novel mechanisms for overcoming drug resistance can offer promising opportunities for market players. Development of affordable biosimilars can reduce treatment costs.

Key Features of the Study:

• This report provides in-depth analysis of the global castrate resistant prostate cancer market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global castrate resistant prostate cancer market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson & Johnson, Astellas Pharma, Sanofi, Dendreon, Bayer, and others
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global castrate resistant prostate cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global castrate resistant prostate cancer market

Detailed Segmentation-

• By Therapy Type
• Hormonal Therapy
• Immunotherapy
• Chemotherapy
• Radiotherapy
• By Drug Class
• Antineoplastic
• Non-steroidal Antiandrogen
• Corticosteroids
• Microtubule Inhibitor
• Others
• By Route of Administration
• Oral
• Injectable
• By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• By Region
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
• Company Profiles:
• Trelleborg Sealing Solutions
• Freudenberg Group
• Parker Hannifin Corp
• Saint-Gobain
• Bal Seal Engineering, Inc.
• Flexan
• Marco Rubber & Plastics
• Morgan Polymer Seals
• Minnesota Rubber and Plastics
• Precision Associates, Inc.
• IDEX Health & Science LLC
• Apple Rubber Products
• Technetics Group
• Sterne S.A.S.
• ResMed
• West Pharmaceutical Services, Inc.